Skip to Main Content


This podcast is produced by pharmacy faculty to supplement study material and provide relevant drug and professional topics. We're hoping that our real-life clinical pearls and discussions will help you stay up-to-date and improve your pharmacy knowledge.

How Do I Listen?

HelixTalk is available via Apple Podcasts (or by searching for HelixTalk), by subscribing to our RSS feed, subscribing to our mailing list, or by listening to any episode in your browser (below).

Subscribe to Our Mailing List

HelixTalk Episodes

HelixTalk #142 - New Gains in Weight Loss Pharmacotherapy

Date posted: January 18, 2022, 6:00 am

In this episode, we will build up on our previous Weight loss Pharmacotherapy Episode, episode #13 to discuss updates in guidelines, prevention of obesity from comorbidity standpoint, and new treatment agents for weight-loss with a particular focus on Contrave (naltrexone/bupropion), Saxenda (liraglutide), and Wegovy (semaglutide).

HelixTalk #141 - What You Need to Know about Hepatorenal Syndrome: New Definitions, Treatments, and Clinical Pearls

Date posted: December 28, 2021, 6:00 am

In this episode, we provide a concise overview of the diagnosis and treatment of hepatorenal syndrome-acute kidney injury (HRS-AKI) with a focus on the new HRS-1 definition (now called HRS-AKI), new data with terlipressin, and the AASLD 2021 guidelines.

HelixTalk #140 - The Ultimate Guide to SSRIs: An In-Depth Drug Class Review

Date posted: December 7, 2021, 6:00 am

In this episode, we review the pharmacology, indications, adverse effects, and unique drug characteristics of the most common SSRIs on the market.

HelixTalk Episode #139 - They Did What?! FDA Approval of Aducanumab for Alzheimer’s Disease

Date posted: November 16, 2021, 6:00 am

In this episode, we discuss the recent accelerated approval of the new monoclonal antibody-based treatment agent, aducanumab (Aduhelm), by the FDA. We dive into the drug approval process, the efficacy and safety data, and the behind-the-scenes story of the FDA approval. Furthermore, we will present the controversy behind the approval and what it means for stakeholders.